Ramsay Healthcare – FY18

Ramsay Healthcare reported FY18 results in-line with market consensus, however, the FY19 guidance was below expectations.

Underlying earnings increased 7% in FY18 and that growth rate is likely to slip to 4 – 5% in FY19. With the stock on a forward yield of 2.7% we see further downside risk to the share price in the short-term.

You’re not a member!  Trial today

RHC is a high quality business and we’ll be watching for the next Algo Engine buy signal.

Material earnings benefits from new hospital  projects are expected in the coming years; we see both Healthscope and Ramsay Healthcare as long-term value plays with a defensive yield.

Buy Healthscope today and remain patient for the entry condition into Ramsay.

 

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.